BMJ report into top-selling diabetes drug raises concerns about the drug regulatory system
British drug regulators say GlaxoSmithKline's controversial diabetes pill Avandia should be pulled from the U.K. market because of concerns that the drug can increase the risk of heart attacks.The Medicines and Healthcare products Regulatory Agency says an independent panel of experts concluded...
"In order to learn from our mistakes, we must improve the quality of safety data from clinical trials on all new health care interventions, not just antidiabetic drugs," he says.
"Ten years after the release of rosiglitazone, we still cannot accurately quantify the harm to which we were exposing our patients," he says.
BMJ report into top-selling diabetes drug raises concerns about the drug regulatory system
A BMJ investigation into the top-selling diabetes drug rosiglitazone (Avandia) raises concerns about its safety and the whole system by which drugs are evaluated, regulated, and promoted around ...
Tue 7 Sep 10 from PhysOrg
BMJ report into top-selling diabetes drug raises concerns about the drug regulatory system, Tue 7 Sep 10 from Eurekalert
UK wants GSK's Avandia pulled as EU reviews safety
LONDON (Reuters) - GlaxoSmithKline's diabetes drug Avandia should be pulled from sale because of concerns about heart risks, British drug regulators said on Monday ahead of a special European ...
Sun 5 Sep 10 from Reuters
Investigation Reveals More Woes for Rosiglitazone
(MedPage Today) -- On July 15--a day after the FDA completed two days of hearings on rosiglitazone (Avandia)--a British advisory commission on drugs concluded that the product should be withdrawn ...
Sun 5 Sep 10 from MedPageToday
UK regulators want Avandia diabetes pill pulled
British drug regulators say GlaxoSmithKline's controversial diabetes pill Avandia should be pulled from the U.K. market because of concerns that the drug can increase the risk of heart attacks.The ...
Mon 6 Sep 10 from R&D Mag
- Pages: 1
Total number of sources: 5
Bookmark
